MAC                                                    bladder(9)
 _________________________________________________________________
  methotrexate.... 30 mg/sqm IV days 1 and 8.
  adriamycin...... 30 mg/sqm IV day 1.
  cytoxan......... 300 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 21 days.

  reference...
    Tannock IF.  Gospodarowicz M.  Evans WK. Chemotherapy for 
    metastatic transitional carcinoma of the urinary tract. A 
    prospective trial of methotrexate, adriamycin, and 
    cyclophosphamide (MAC) with cis-platinum for failure. Cancer.  
    51(2):216-9, 1983 Jan 15. 
  abstract...
    Fifty-two patients with metastatic transitional cell carcinoma 
    (TCC) of the urinary tract were treated with methotrexate, 
    Adriamycin and cyclophosphamide (MAC). Objective responses 
    lasting at least three months were seen in 15 (two CR, 13 PR) 
    of 38 patients with measurable disease (response rate = 39%, 
    with 95% confidence limits 24-57%). Median duration of 
    response was six months (range, 3-12 months). In addition, 
    there was clinical or other evidence of response for greater 
    than or equal to 3 months in four of 14 patients with 
    evaluable but nonmeasurable lesions. Sixteen patients who 
    failed or relapsed after MAC chemotherapy received 
    cis-platinum and none responded. MAC chemotherapy can provide 
    significant palliation to some patients with TCC and is 
    usually better tolerated than cis-platinum.